



Have **everything** to
be ready for **anything**

Rely on an extensive portfolio of tailored TaqPath COVID-19 testing solutions to meet your lab's evolving needs

The US Food and Drug Administration (FDA) authorized the Applied Biosystems™ TaqPath™ COVID-19 Combo Kit for emergency use just days after the World Health Organization (WHO) declared COVID-19 a global pandemic. Since then, Thermo Fisher Scientific has continued to grow and enhance the Applied Biosystems™ TaqPath™ testing portfolio, enabling an uninterrupted product supply to support your lab's evolving needs—now and in the future.

Explore our extensive portfolio of COVID-19 testing solutions, geared to help your lab keep up:

TaqPath COVID-19 Combo Kit

- **Accessible workflow**—for use on seven Applied Biosystems™ real-time PCR systems using six authorized sample types
- **S gene advantage**—can signal the presence of the S gene 69-70del mutation and allow for potential early identification of the Omicron variant (B.1.1.529)
- **Fast turnaround time**—complete your workflow in less than three hours

Thermo Fisher Scientific™ Amplitude™ Solution

- **Compatibility**—utilizes the Applied Biosystems™ TaqPath™ COVID-19 High-Throughput Combo Kit
- **High-throughput scalability**—highly automated, scalable processing of 100 to 8,000 COVID-19 samples per day, requiring only four full-time employees (FTEs)
- **Proven technology**—qualitative detection of nucleic acid from the SARS-CoV-2 virus in nasopharyngeal and anterior nasal swab specimens, as well as saliva specimens, from individuals suspected of COVID-19 by their health care provider, collected using SpectrumDNA™ SDNA-1000 Saliva Collection Devices
 - May help identify samples that contain the Omicron variant
 - Uses a multi-target assay design to compensate for emerging SARS-CoV-2 variants and mutations
- **Secured supply**—need-based allocation for consistent supply of assays and consumables

Explore our extensive portfolio of Applied Biosystems™ TaqPath™ COVID-19 testing solutions, geared to help your lab keep up:

TaqPath™ COVID-19, Flu A, Flu B Combo Kit

- **Single test**—detects and differentiates SARS-CoV-2 and influenza (flu) A and B viruses, and helps diagnose and monitor the spread of COVID-19 and the flu
- **Highly sensitive and specific**—multi-target assay design provides robust performance for detecting SARS-CoV-2 and flu A and B viruses, and compensates for emerging SARS-CoV-2 variants and mutations
- **Complete solution for clinical labs**—Applied Biosystems™ Pathogen Interpretive Software automatically converts genetic analysis data into a readable report, helping reduce the risk of user interpretation error

TaqPath™ COVID-19 Pooling Kit

- **Increased sample processing efficiency**—pool multiple samples for a single test using a single kit for pool and deconvolution testing
- **Highly accurate and specific**—detect with 100% sensitivity*
- **Affordable and scalable**—add to existing testing menu and infrastructure while maintaining low operational costs
- **Seamless integration**—compatible with most current laboratory information management system (LIMS) platforms

TaqPath™ COVID-19 Fast PCR Combo Kit 2.0

- **Fast, direct-to-PCR workflow from raw saliva**—increased speed from raw saliva samples (no preservatives) to results, enabling widespread, high-frequency testing
- **Simple and affordable**—workflow from raw saliva collection direct to PCR (bypassing RNA extraction) helps save supplies, reagents, and personnel costs
- **Gold-standard technology**—a PCR-based, sensitive COVID-19 test, offering a limit of detection (LOD) of 750–1,000 GCE/mL from raw saliva
- **Innovative, multi-target assay design**—eight targets across three regions (*orf1a*, *orf1b*, N genes) compensate for emerging SARS-CoV-2 mutations, helping provide confidence in results now and into the future

TaqPath™ COVID-19 RNase P Combo Kit 2.0

- **Human sample confirmation**—the RNase P gene serves as an endogenous control, helping ensure sample integrity, quality, and extraction
- **Innovative, multi-target assay design**—eight targets across three regions (*orf1a*, *orf1b*, N genes) compensate for emerging SARS-CoV-2 mutations, helping provide confidence in results now and into the future
- **Sensitive detection of symptomatic and asymptomatic individuals**—detects active infections in patients, as well as asymptomatic individuals, using a PCR-based test with a 75 GCE/mL LOD
- **Affordable and scalable**—add to your existing COVID-19 test menu using some of the most widely used PCR systems in the world

* The TaqPath COVID-19 Pooling Kit has targeted specificity to 100% of currently available, complete genomes for SARS-CoV-2.

Instrument compatibility and product ordering information

	TaqPath COVID-19					
	Combo Kit	Fast PCR Combo Kit 2.0	RNaseP Combo Kit 2.0	Flu A, Flu B, Combo Kit	Pooling Kit	High-Throughput Combo Kit
Unit size	1,000 rxn	1,000 rxn	1,000 rxn	1,000 rxn	200 rxn	20,000 rxn
Cat. No.	A47814	A51606	A51333	A49868	A49918	A49869
QuantStudio™ 5 Real-Time PCR instrument						
0.1-TAP 96w	•					
0.2-TAP 96w	•	•	•	•		
TAP 384w	•					
QuantStudio™ 7 Flex Real-Time PCR instrument 384w	•	•	•	•	•	
7500 Real-Time PCR instrument	•					
7500 Fast Real-Time PCR instrument	•					
7500 Fast Dx Real-Time PCR instrument	•			•		
Amplitude Platform						•

TAP - TaqMan™ Array Plates

 Learn more at thermofisher.com/taqpathkits

applied biosystems